PSYCHOSIS TRIGGERED BY ZOLPIDEM: CLINICAL OBSERVATIONS FROM TWO ADULT CASES.
Main Article Content
Keywords
.
Abstract
Zolpidem, a non-benzodiazepine hypnotic commonly prescribed for insomnia, is generally considered safe for short-term use. However, adverse neuropsychiatric reactions, including psychosis, though rare, have been increasingly reported.
References
1. Sanger DJ, Zivkovic B. The pharmacology and mechanism of action of zolpidem. CNS Drug Rev. 1998;4(4):323–40.
2. Holm KJ, Goa KL. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59(4):865–89.
3. Tsai MJ, Huang TL. Zolpidem-induced psychosis in a patient with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):739–40.
4. Victorri-Vigneau C, Feuillet F, Wainstein L, Grall-Bronnec M, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64(2):198–209.
5. Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155–62.
6. Victorri-Vigneau C, Feuillet F, Wainstein L, Grall-Bronnec M, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64(2):198–209.
7. Hoque R, Chesson AL Jr. Z-drug dependency and withdrawal: Zolpidem and Zaleplon dependence. J Clin Sleep Med. 2009;5(6):498–9.
8. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98(10):1371–8.
2. Holm KJ, Goa KL. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59(4):865–89.
3. Tsai MJ, Huang TL. Zolpidem-induced psychosis in a patient with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):739–40.
4. Victorri-Vigneau C, Feuillet F, Wainstein L, Grall-Bronnec M, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64(2):198–209.
5. Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155–62.
6. Victorri-Vigneau C, Feuillet F, Wainstein L, Grall-Bronnec M, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64(2):198–209.
7. Hoque R, Chesson AL Jr. Z-drug dependency and withdrawal: Zolpidem and Zaleplon dependence. J Clin Sleep Med. 2009;5(6):498–9.
8. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98(10):1371–8.